vTv Therapeutics Inc. Quarterly Debt-to-equity in % from Q2 2016 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
vTv Therapeutics Inc. quarterly Debt-to-equity history and growth rate from Q2 2016 to Q2 2024.
  • vTv Therapeutics Inc. Debt-to-equity for the quarter ending June 30, 2024 was -896 %, a 471% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 -896 -739 -471% Jun 30, 2024
Q1 2024 -213 -7.4 -3.59% Mar 31, 2024
Q4 2023 -123 +102 +45.2% Dec 31, 2023
Q3 2023 -142 +48.4 +25.4% Sep 30, 2023
Q2 2023 -157 -27.1 -20.9% Jun 30, 2023
Q1 2023 -206 -158 -329% Mar 31, 2023
Q4 2022 -225 -197 -695% Dec 31, 2022
Q3 2022 -190 -171 -902% Sep 30, 2022
Q2 2022 -130 -111 -602% Jun 30, 2022
Q1 2022 -48 -28.2 -142% Mar 31, 2022
Q4 2021 -28.3 -6.37 -29.1% Dec 31, 2021
Q3 2021 -19 +8.95 +32% Sep 30, 2021
Q2 2021 -18.5 +12.7 +40.8% Jun 30, 2021
Q1 2021 -19.8 +16.8 +45.8% Mar 31, 2021
Q4 2020 -21.9 +18.5 +45.8% Dec 31, 2020
Q3 2020 -27.9 +11.3 +28.8% Sep 30, 2020
Q2 2020 -31.2 +15.5 +33.2% Jun 30, 2020
Q1 2020 -36.6 +14.5 +28.4% Mar 31, 2020
Q4 2019 -40.4 +2.95 +6.8% Dec 31, 2019
Q3 2019 -39.2 +1.51 +3.71% Sep 30, 2019
Q2 2019 -46.6 -14.4 -44.6% Jun 30, 2019
Q1 2019 -51.1 -23.4 -84.3% Mar 31, 2019
Q4 2018 -43.4 -16.8 -63.3% Dec 31, 2018
Q3 2018 -40.7 -16.1 -65% Sep 30, 2018
Q2 2018 -32.3 -10.5 -48.4% Jun 30, 2018
Q1 2018 -27.7 -9.48 -52% Mar 31, 2018
Q4 2017 -26.6 -11.3 -73.8% Dec 31, 2017
Q3 2017 -24.7 -13.3 -117% Sep 30, 2017
Q2 2017 -21.7 -11.2 -107% Jun 30, 2017
Q1 2017 -18.3 Mar 31, 2017
Q4 2016 -15.3 Dec 31, 2016
Q3 2016 -11.4 Sep 30, 2016
Q2 2016 -10.5 Jun 30, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.